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Abstract The arrival of targeted therapies has presented
both a conceptual and a practical challenge in the treatment
of patients with advanced non-small cell lung carcinomas
(NSCLCs). The relationship of these treatments with spe-
cific histologies and predictive biomarkers has made the
handling of biopsies the key factor for success. In this
study, we highlight the balance between precise histolog-
ical diagnosis and the practice of conducting multiple
predictive assays simultaneously. This can only be
achieved where there is a commitment to multidisciplinary
working by the tumor board to ensure that a sensible pro-
tocol is applied. This proposal for prioritizing samples
includes both recent technological advances and the some
of the latest discoveries in the molecular classification of
NSCLCs.
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Introduction
The classification of primary lung carcinomas is probably one
of the least precise among all the solid tumors. Paradoxically,
however, it is one of the most reproducible. The lung
pathology field has not only been static, as recently mentioned,
but also perceived as uninteresting [1]. This has come about
due to a set of factors which can be better understood from a
historical perspective. The discovery that some of these car-
cinomas, i.e., small cell carcinomas (SCLCs), responded
incredibly well to chemotherapy led to a lack of interest in the
correct classification of lung carcinomas. It is a situation that
continues even today. This therapeutic discovery gave rise to
the use of the intelligent term ‘‘non-small cell lung carcinoma
(NSCLC)’’ and to a tolerance of the lack of precision.
According to Edwards et al., this nomenclature was suggested
in 1984 by Chuang et al. and accepted from then on during the
pre-immunohistochemistry (IHC) era to decrease the risk of
over-interpreting small biopsy specimens [2–4]. Over the
years, the term has been extended to surgical specimens,
clinical trials, etc. [5, 6].
The term ‘‘large cell carcinoma (LCC)’’ was defined by
the 2004 WHO classification as one of exclusion [7]. It is
also misused for two main reasons:
(a) In the setting of surgical specimens, it gives rise to the
possibility of giving such a name to all difficult cases
with no obvious keratin (squamous cell carcinomas,
SCCs) or gland formation (adenocarcinomas, ACs).
(b) It is frequently applied as a synonym of non-small
cell carcinoma in small thoracic biopsies [7–9].
A few years ago, there was a sudden interest, which has
continued to grow, in the histology of lung cancer [10].
This can be explained by various factors. Firstly, ACs have
treatable molecular alterations: mainly EGFR mutations
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and ALK translocation [11–14]. Secondly, some targeted
agents should not be used in SCCs. This is not only because
they do not provide better response rates (pemetrexed), but
also because their use in this histological type is associated
with life-threatening complications (i.e., bevacizumab)
[15–17]. As if we had not learned our lesson previously,
another imprecise term is emerging: ‘‘non-squamous his-
tology’’ [15, 18].
As such, the current therapeutic situation of lung cancer
demonstrates that establishing a treatment requires a precise
histological diagnosis. Many treatable molecular alterations
are linked to specific histological types. Equally, diagnosis
must be reasonable. If we exhaust the sample during clas-
sification, we will not be able to produce predictive bio-
markers [19, 20]. Certain considerations are, therefore,
necessary. Although there appears to be complete speci-
ficity for AC or SCC for several driver mutations, some
poorly differentiated ACs may be classified as SCC due to
the presence of squamoid features [21]. Moreover, a sig-
nificant number of those poorly differentiated ACs may
have treatable molecular alterations [22]. For example, up
to 18 % of so-called squamoid subtype ACs can harbor
EGFR mutations [23]. The practical implication is that it is
probably better to use the ‘‘NSCLC-NOS’’ (not otherwise
specified) category when there is inconclusive evidence of
squamous or glandular differentiation.
Lung carcinoma classification for non-pathologists
In the paragraphs that follow, we shall discuss certain
aspects which are, perhaps, less well-known to clinicians or
pathologists with less experience in thoracic pathology.
While SCLCs are not the subject of this study, it is
useful to include a paragraph about them. Currently, we
recommend confirmation with IHC of all SCLCs which
appear as such in the study with hematoxylin and eosin
(H&E), i.e., scant cytoplasm, granular nuclear chromatin
with nucleoli inconspicuous or absent and high mitotic rate.
For the IHC confirmation, the following are sufficient: two
neuroendocrine differentiation markers (CD56, chromogr-
anin or synaptophysin); a pankeratin AE1–AE3 with fre-
quent ‘‘dot-like’’ pattern; TTF-1 (70–90 % positive) and a
very high proliferative index by Ki-67 (70–100 %). This is
very important in making the differential diagnosis with
lymphoma, melanoma, and other lung neoplasias: poorly
differentiated SCCs, large neuroendocrine cell carcinoma,
and carcinoid tumors, especially [24, 25]. Two aspects
must be taken into account:
(a) Neoplasias with neuroendocrine differentiation can
show positivity for p63. This includes some 77 % of
SCLCs [26].
(b) SCLCs observed outwit the typical bronchial biopsy
with crush artifact, and chromatin stretching have an
appearance with which we, pathologists, are not
familiar, i.e., very well-conserved cells with visible
nucleus, greater size, etc. Examples might include
SCLCs observed in a pulmonary core-needle biopsy,
in a wedge lung resection specimen or in a metastasis.
These unfamiliar appearances can present huge
difficulties in differential diagnosis [25].
Furthermore, ACs and SCCs represent the two major
types of NSCLCs. Distinguishing between the two histo-
logical types can appear extremely difficult by routine light
microscopy, particularly in small biopsies and cytology
samples. This can affect up to 35 % of cases [27]. In the
case of NSCLCs, the use of IHC is essential where a
specific, conclusive diagnosis cannot be produced. Indeed,
we can only make such a diagnosis where we identify
keratinization in SCCs or gland formation in ACs. As such,
probably the most accepted antibody pair in the literature is
that formed by TTF-1 (marker of glandular differentiation)
and p63 (marker of squamous differentiation) [28]. In
additional, SCCs also tend to be positive for desmocollin-3
(the most specific marker) and CK5/6 (the most sensitive
marker) [27]. ACs, however, stain with Napsin A (the most
specific marker) and CK7 (the most sensitive marker) [27].
Interestingly, desmocollin-3 (DCS3) was the top differen-
tially expressed gene in our own microarray comparison
between lung ACs and SCCs [29]. This finding has been
independently confirmed by other groups [27, 30].
It must be stressed that analytical and post-analytical
aspects (interpretation) can influence the supposed speci-
ficity and sensitivity of an antibody. Given this consider-
ation, it is useful, for example, to recall that genuine
staining of p63 must be intensive and extensive. Faint or
focal immunostaining for p63 should be considered non-
specific until there is proof that it is not [9, 27, 28, 31–35].
Recent studies show the value of p40 (DNp63) as a more
specific marker of squamous differentiation [36–38].
Another idea is to use double staining protocols combining
a nuclear and a cytoplasmic/membranous antibody (for
example, CK7-p63 and CK5/6-TTF-1) to reduce the
number of slides necessary [27]. However, we should
always bear in mind that methodologies taken to raise
specificity may also lower the likelihood of clinical
application. For example, new antibodies or protocols may
not be easy to implement or interpret.
Sample prioritization
While we firmly believe as pathologists in the importance of
the correct histological subtyping of carcinomas of the lung,
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we also understand that it is not always possible in the real
world. There is currently no consensus on how to prioritize
the different predictive assays that are frequently performed
in different laboratories using different approaches. These
include, for example, H&E and IHC for diagnosis, accurate
histological subtyping and some predictive biomarkers,
fluorescence in situ hybridization (FISH) for ALK translo-
cation, and PCR for EGFR mutations [35, 39, 40]. The
‘‘tissue sparing’’ algorithm that we propose for molecular
tests in small thoracic samples is depicted in Fig. 1 [41–43].
This approach not only saves time and tissue, but will also
provide realistic information on the true incidence and
overlap of the different molecular alterations. These con-
siderations are not merely academic. Rather, they influence
the cost of drugs and their biomarkers [44].
In order to minimize the loss of material, the following
are suggested:
1. Sufficient multidisciplinary communication, oncolog-
ical, and pathological to put the paraffin block in the
microtome as few times as possible;
2. Reasonable use of classificatory IHC with a restricted
panel of antibodies. While this increases the percent-
age of ‘‘NSCLC-NOS’’, the sample is preserved for
future studies on therapeutic targets [27, 35].
Figure 2 shows how sample prioritization and biomarker
information are integrated into patient care.
Predictive biomarkers
As a result of our experience in recent years, we believe
that a protocol similar to that depicted in Fig. 1 would
provide information on multiple predictive biomarkers [22,
28, 41, 42, 45]. Although some aspects of our approach
have already been implemented, others remain theoretical
[42]. Ideally, the protocol should be validated prospec-
tively with an intention-to-treat philosophy. Our protocol
has several advantages. Firstly, the sample is sectioned in
as few steps as possible to decrease tissue waste at the
























































































Fig. 1 A realistic approach for sample prioritization for the study of
predictive biomarkers in patients with advanced lung ACs. Route A is
for cases that require classificatory IHC while route B is for cases that
are diagnosed based on the H&E alone. The relative frequency of the
different genetic alterations is shown in parenthesis. Data from ROS1
translocation is taken from the literature [43]. The other percentages
come from our own experience [41, 42], and unpublished data
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Secondly, this approach permits the combination of dif-
ferent methodologies: IHC, in situ hybridization and PCR.
This is important because, currently, it is not realistic to
‘‘multiplex’’ the analytical phase of, for example, mutation,
amplification, translocation, and overexpression detection.
Thirdly, it allows the order of the different biomarkers to
be changed depending on estimated prevalence, histologi-
cal characteristics, drug approvals or access to clinical
trials, or compassionate use. For example, ACs with lepidic
(formerly ‘‘bronchioloalveolar’’), papillary or micropapil-
lary components are commonly associated with EGFR
mutations, papillary growth has also been linked with
BRAF V600E mutated ACs, and signet-ring cells are typ-
ically present in ALK positive lung ACs [46–49]. Fourthly,
it also allows the methodology to be changed. This is
feasible because most IHC and in situ hybridization tests
are performed on 3–5 lm sections, and there are recent
PCR methods that allow mutation testing from a single
5 lm section [50–52]. Fifthly, simultaneous testing of at
least some of the biomarkers (those included in step A3/B2
and step A4/B3) will give us the response as to whether
they are truly mutually exclusive or not, as well as the true
prevalence in a given population. If they are not mutually
exclusive, we will not leave potentially positive patients
without testing. This is especially important now as, where
methodological caveats can be reasonably discounted, we
are beginning to accept the existence of:
(a) Molecular heterogeneity: recently published discor-
dance rates between primary tumors and metastases
were 14 % for EGFR mutations and 13.5 % for ALK
overexpression [53, 54];
(b) Overlap in predictive markers. For example, ALK
translocations may be identified in both EGFR and
HER2 mutant patients [55, 56].
Ideally, an H&E is conducted first to confirm the
malignant nature of the disease. If the tumor shows
malignant glands, an AC can be diagnosed with certainty.
If not, a couple of classificatory IHC stains is probably
sensible (step A2). Step A3/B2 involves simultaneous
testing for EGFR mutations and for ALK translocation.
Almost everyone will agree that, in patients with advanced
lung ACs, it is necessary to know those two biomarkers.
However, there is no consensus on whether testing should
be simultaneous or sequential. Nor is there consensus on
the methodology to be used [35, 39, 57, 58]. A wide variety
of methods have been applied to EGFR mutation analysis.
Although direct sequencing is still probably the most fre-
quently used method, in recent years commercial real time
PCR assays have become increasingly popular [41, 45].
Although FISH is currently the only approved method to
identify potential responders to crizotinib through the
presence of the ALK translocation, ALK IHC may also
prove useful in this setting [57].
The remaining biomarkers (step A4/B3) represent a
more innovative approach to lung cancer targeted thera-
pies. It is probably wise to check the status of KRAS [59].
In addition, patients with ROS rearrangements may also
respond to crizotinib [43]. We should also extract DNA
again and look for mutations in HER2 and BRAF [60–62].
A final H&E section will re-assure us as to how many
tumor cells we have left for the latter assays and the
possibility of producing more biomarkers in the future
Fig. 2 A simplified view of an
integrated pathway for the study
of predictive biomarkers in
patients with advanced
NSCLCs. There are two
interesting aspects. a If the
sampling is managed by the
tumor board, there will be better
sample prioritization than has
happened previously. b There is
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(i.e., MET amplification, MET overexpression, and RET
rearrangement) [63–65].
To conclude, the final consideration is: what is the
minimum number of tumor cells needed to conduct these
tests? For IHC, counts of 2,000 tumor cells are recom-
mended [66]. In the case of FISH, 100 cells are sufficient
[50, 66]. For PCR techniques, it is very important to know
their limit of detection (LOD) and to work with a safety
margin. For example, if the LOD of direct sequencing is
30 %, the percentage of tumor cells should ideally be
40–50 % [41, 45, 66, 67]. In the case of real time PCR with
a LOD of 1–5 %, we must be aware of the risk of false
negatives when the percentage of tumor cells is below
10 % [41, 45, 66, 67].
Unfortunately, most of the advances in personalized
treatment of NSCLCs have been confined to the treatment
of patients with ACs. However, better molecular charac-
terization of SCCs is enabling this subgroup to become a
growing area of interest. As such, specific molecular
defects such as FGFR1 amplifications, DDR2 mutations,
PI3KCA amplifications and mutations will become part of
the routine molecular diagnostic workup of SCCs [68–71].
Lessons learned from ACs should help to make these
exciting findings a success story for the treatment of SCCs.
In conclusion, we have presented a realistic approach to
lung AC targeted therapies. This includes accurate histo-
logical subtyping, as well as sample prioritization to
release information on as many predictive biomarkers as
possible.
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